“You could see him diminishing.” Today, Carr is trying a new treatment called Leqembi that has been shown to modestly slow the disease for people in the initial stages of Alzheimer’ ...
They based this hypothesis on the fact that newly approved monoclonal antibody medications — including lecanemab (Leqembi) and donanemab (Kisunla) — have had the unintended outcome of raising ...
Even though you cannot stop AD from getting worse, with LEQEMBI, you can take steps to slow how fast it progresses.[3] That's why identifying symptoms early on is so important.[1] "In recent years ...
Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.